Cumberland Pharmaceuticals, Inc. (OQ:CPIX)
Business Focus: Generic Pharmaceuticals
Apr 30, 2024 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
Apr 02, 2024 04:05 pm ET
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants
Nov 07, 2023 03:05 pm ET
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date.
Oct 31, 2023 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.
Oct 10, 2023 04:05 pm ET
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
NASHVILLE, Tenn., Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ® (telavancin) injection in children 2 to 17 years of age. Vibativ is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as well as complicated skin and skin structure infections (cSSSIs) caused by certain gram-positive bacteria
Aug 01, 2023 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.
Jun 26, 2023 09:00 am ET
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
NASHVILLE, Tenn., June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs1. Caldolor (ibuprofen) injection, is an intravenous non-steroidal anti-inflammatory drug (NSAID) approved by the FDA for the treatment of pain and fever in adults and children. The results of this published study supported the recent FDA approval of Caldolor in infants 3
May 23, 2023 09:00 am ET
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial,
May 15, 2023 09:00 am ET
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS
Caldolor® is the only injectable non-opioid approved for treating pain in infants
May 09, 2023 04:05 pm ET
Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update
NASHVILLE, Tenn., May 9, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of $1.7 million, or $0.11 a share. The Company ended the first quarter with $89 million in total assets, $53 million in total liabilities, and $36 million of shareholders' equity.
May 02, 2023 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.
Nov 08, 2022 03:05 pm ET
Cumberland Pharmaceuticals Reports 41% Revenue Growth
Company Also Delivers Growing Cash Flow from Operations
Nov 01, 2022 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022.
Nov 01, 2022 09:20 am ET
CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST
NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today that it has moved its headquarters to the Broadwest campus in the Vanderbilt/West End corridor of Nashville. The company is focused on its mission of advancing patient care through the delivery of high quality medicines.
Aug 09, 2022 04:05 pm ET
Cumberland Pharmaceuticals Reports 14% Revenue Growth
Expanding portfolio of FDA approved brands driving double digit growth
Aug 08, 2022 09:25 am ET
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues
Aug 02, 2022 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022.
Jul 19, 2022 09:25 am ET
CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors.
May 10, 2022 04:05 pm ET
Cumberland Pharmaceuticals Reports 6% Revenue Growth
The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update
May 09, 2022 09:15 am ET
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
Verity Pharmaceuticals will feature Sancuso across the U.S. through its established oncology commercial organization and customer network
May 03, 2022 04:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn., May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022.
Mar 31, 2022 09:20 am ET
TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST
Vibativ® treats patients with multidrug-resistant infections
Mar 08, 2022 03:05 pm ET
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a company update. Net revenues totaled $36 million, resulting in $6 million in cash flow from operations.
Mar 01, 2022 03:05 pm ET
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS
NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results and provide a company update after the market closes on Tuesday, March 8, 2022.
Jan 04, 2022 08:15 am ET
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA
NASHVILLE, Tenn. and BEDMINSTER, N.J., Jan. 4, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company focused on discovering and delivering novel medicines.
Dec 01, 2021 09:45 am ET
Thinking about buying stock in Arbutus Biopharma, Beyondspring, Cumberland Pharmaceuticals, Delta Air Lines, or T2 Biosystems?
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, BYSI, CPIX, DAL, and TTOO.
Nov 30, 2021 10:27 am ET
Thinking about buying stock in Cumberland Pharmaceuticals, AT&T, Clarus Therapeutics, RLX Technology, or Norwegian Cruise Line?
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CPIX, T, CRXT, RLX, and NCLH.
Nov 29, 2021 03:05 pm ET
Caldolor® Now FDA Approved For Pre-Operative Administration
NASHVILLE, Tenn., Nov. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever may now be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.
Nov 09, 2021 03:05 pm ET
Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., Nov. 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2021 financial results. Net revenues from continuing operations during the quarter were $8.1 million and totaled $27.7 million for the first nine months of 2021, up 1.8% compared to the same period in 2020. The company also recorded an additional $0.5 million in revenue during the third quarter and $1.5 million year to date, associated with divested product rights for two brands it is no longer distributing.
Nov 02, 2021 04:05 pm ET
Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results
NASHVILLE, Tenn., Nov. 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021. A conference call and live internet webcast will be held on November 9 at 4:30 p.m. Eastern Time to discuss the results.
Sep 29, 2021 09:25 am ET
Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis
NASHVILLE, Tenn., Sept. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today the national launch of its RediTrex® (methotrexate) line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.
Aug 10, 2021 04:05 pm ET
Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter were $9.1 million and totaled $19.6 million for the first half of 2021. The company also recorded an additional $500,000 in revenue during the second quarter and $1 million year to date, associated with divested product rights for two brands it is no longer distributing.
Aug 03, 2021 04:05 pm ET
Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results
NASHVILLE, Tenn., Aug. 3, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021. A conference call and live internet webcast will be held on Tuesday, August 10, 2021, at 4:30 p.m. Eastern Time to discuss the results.
Jul 26, 2021 09:25 am ET
Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020
NASHVILLE, Tenn., July 26, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2020 Sustainability Report, which details the company's activities pertaining to environmental, social and governance (ESG) matters.
Jun 21, 2021 09:20 am ET
Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients
NASHVILLE, Tenn., June 21, 2021 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ® (telavancin) in treating secondary bacterial infections in COVID-19 patients – particularly those with other significant health problems, such as obesity, diabetes and heart disease.
Nov 17, 2020 10:05 am ET
Introducing RediTrex®, A New Methotrexate Delivery System
NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.
Nov 10, 2020 03:05 pm ET
Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million. The company also recorded an additional $750,000 in revenue during the third quarter associated with divested product rights for two brands it is no longer distributing.
Nov 03, 2020 03:05 pm ET
Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results
NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after the market closes on Tuesday, Nov. 10, 2020. A conference call and live internet webcast will be held on Tuesday, Nov. 10, 2020, at 4:30 p.m. Eastern Time to discuss the results.
Aug 04, 2020 04:05 pm ET
Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2020 financial results and Company update after the market closes on Tuesday, Aug. 11, 2020. A conference call and live internet webcast will be held on Tuesday, Aug. 11, 2020, at 4:30 p.m. Eastern Time to discuss the results.
Jul 20, 2020 08:35 am ET
Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients
NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demonstrate Caldolor® (ibuprofen) Injection significantly reduces the quantity of opioids required to manage pain after a traumatic injury with fracture. In addition, the time to first narcotic medication was longer in the Caldolor group than with hospital standard of care. Further, pain was managed better in the Caldolor® group co
May 26, 2020 04:05 pm ET
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
NASHVILLE, Tenn., May 26, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis.
May 20, 2020 04:05 pm ET
Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update
NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results. Net revenues from continuing operations during the quarter were $8.3 million. Total revenues were $9.1 million, as the company recorded an additional $750,000 in revenue in the first quarter associated with divested product rights.
May 15, 2020 04:40 pm ET
Cumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results
NASHVILLE, Tenn., May 15, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company update after the market closes on Wednesday, May 20, 2020. A conference call and live Internet webcast will be held on Wednesday, May 20, 2020 at 4:30 p.m. Eastern Time to discuss the results.
May 11, 2020 04:10 pm ET
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
NASHVILLE, Tenn., May 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces two new publications detailing the sustained in vitro potency of Vibativ® (telavancin) as part of a 7-year antimicrobial surveillance program. Both publications were part of continued surveillance of telavancin activity since 2011. The first publication tested a global collection of 24,408 Gram-positive clinical isolates, and the second publication tested a U.S. collection of 15,882 S. aureus isolates. All isolates were collected from the SENTRY An
Apr 28, 2020 09:35 am ET
Cumberland Pharmaceuticals Releases Inaugural Report On Its Environmental, Social And Governance (ESG) Activities
NASHVILLE, Tenn., April 28, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its first Sustainability Report. This report describes the company's activities pertaining to Environmental, Social and Governance (ESG) matters, otherwise known as corporate sustainability. It includes details about Cumberland's community involvement, ethical marketing and drug safety.
Apr 07, 2020 05:00 pm ET
To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units
NASHVILLE, Tenn., April 7, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced an initiative to increase availability of Vaprisol® (conivaptan hydrochloride) injection for treating hyponatremia, associated with critical care patients during the COVID-19 pandemic. Vaprisol is an FDA approved treatment for hyponatremia, a potentially life-threatening condition that can often afflict patients in the Intensive Care Unit ("ICU").
Mar 31, 2020 05:00 pm ET
Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections
NASHVILLE, Tenn., March 31, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced a national initiative to support hospitals and clinics that use Caldolor® (ibuprofen) injection for the treatment of patients with fever, severe hyperthermia and other symptoms associated with COVID-19 infections.
Mar 23, 2020 05:00 pm ET
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
NASHVILLE, Tenn., March 23, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, today announced a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 coronavirus.
Mar 18, 2020 04:05 pm ET
Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019
NASHVILLE, Tenn., March 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and full year 2019 financial results. Net Revenues for the fourth quarter were $13.7 million, and for the full year 2019, Net Revenues totaled $47.5 million, a 17% increase over the prior year.
Mar 17, 2020 09:35 am ET
Caldolor® Demonstrates Favorable Safety Profile In Newborns
NASHVILLE, Tenn., March 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced topline results from a clinical study evaluating the safety and pharmacokinetics of Caldolor® (ibuprofen) Injection in children ranging from birth to six months of age. Topline results from this study indicate that Caldolor was well tolerated overall in this patient population, with no safety concerns noted.
Nov 12, 2019 03:05 pm ET
Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter
NASHVILLE, Tenn., Nov. 12, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced third quarter 2019 financial results with net revenues of $10.4 million, up 22% over the prior year quarter. Year-to-date net revenues were $33.9 million, up 24% from the prior year period. The Adjusted Earnings year-to-date were $3.5 million or $0.22 per diluted share. As of September 30, 2019, Cumberland had over $100 million in total assets, including just under $30 million in cash and marketa
Nov 05, 2019 08:35 am ET
Cumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results
NASHVILLE, Tenn., Nov. 5, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2019 financial results after the market closes on Tuesday, November 12, 2019. A conference call and live Internet webcast will be held on Tuesday, November 12, at 4:30 p.m. Eastern Time to discuss the results.
Oct 15, 2019 09:35 am ET
New Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia
NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Cumberland manufactures and distributes telavancin under the brand name Vibativ®.
Sep 24, 2019 09:35 am ET
Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program
NASHVILLE, Tenn., Sept. 24, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. Food and Drug Administration (FDA) has cleared Cumberland's application to study ifetroban in DMD patients, 7 years of age and older. In addition, Cumberland has been awarded just over $1 m
Aug 14, 2019 04:05 pm ET
Cumberland Pharmaceuticals Reports 14% Revenue Growth In The Second Quarter
NASHVILLE, Tenn., Aug. 14, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced second quarter 2019 financial results with net revenues of $11.6 million, up 14% over the prior year quarter. Year-to-date net revenues were $23.5 million, up 25% from the prior year period. While the GAAP net loss for the second quarter was $(0.5) million, or $(0.04) per share, the Adjusted Earnings for the quarter were $1.6 million or $0.10 per diluted share. As of June 30, 2019, Cumberland had
Aug 07, 2019 01:45 pm ET
Cumberland Pharmaceuticals To Announce Second Quarter 2019 Financial Results
NASHVILLE, Tenn., Aug. 7, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2019 financial results after the market closes on Wednesday, August 14, 2019. A conference call and live Internet webcast will be held on Wednesday, August 14, at 4:30 p.m. Eastern Time to discuss the results.
May 15, 2019 09:35 am ET
Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement For Distribution In China
NASHVILLE, Tenn., May 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced it has entered into an exclusive agreement with China's Winhealth Pharma Group for the licensing rights of Acetadote® (acetylcysteine) Injection, used to prevent or reduce liver damage resulting from acetaminophen overdose, and Caldolor® (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. The agreement will provide Winhealth licensing rights to commercialize both FDA approved drugs in China, the second largest m
May 14, 2019 04:05 pm ET
Cumberland Pharmaceuticals Reports 38% Revenue Growth In The First Quarter
NASHVILLE, Tenn., May 14, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced first quarter 2019 financial results with net revenues of $11.9 million, up 38% over the prior year quarter. At the end of the first quarter, Cumberland had $115 million in total assets, including approximately $34 million in cash and marketable securities.
May 07, 2019 09:35 am ET
Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results
NASHVILLE, Tenn., May 7, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2019 financial results after the market closes on Tuesday, May 14, 2019. A conference call and live Internet webcast will be held on Tuesday, May 14, at 4:30 p.m. Eastern Time to discuss the results.
Mar 29, 2019 10:42 am ET
Cumberland Pharmaceuticals Announces Strategic Review
NASHVILLE, Tenn., March 29, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has commenced a strategic review of its branded product portfolio, as well as its roster of international partners. The Company expects to communicate results from the review during its upcoming report on the first quarter of 2019.
Feb 26, 2019 03:05 pm ET
Cumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%
NASHVILLE, Tenn., Feb. 26, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care, today announced fourth quarter and full year 2018 financial results. Net Revenues for the fourth quarter grew to $13.5 million, an increase of 16% over the prior year period. For the full year 2018, Net Revenues totaled $40.7 million.
Feb 19, 2019 03:05 pm ET
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results
NASHVILLE, Tenn., Feb. 19, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2018 financial results after the market closes on Tuesday, February 26, 2019. A conference call and live Internet webcast will be held on Tuesday, February 26, 2019, at 4:30 p.m. Eastern Time to discuss the results.
Nov 13, 2018 03:05 pm ET
Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results
NASHVILLE, Tenn., Nov. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update. Cumberland has a portfolio of eight U.S. Food and Drug Administration (FDA) approved brands. Net revenues for the quarter were $8.5 million. At the end of the third quarter, Cumberland had $87 million in total assets, including approximately $48 million in cash and marketable securities.
Nov 07, 2018 03:05 pm ET
Cumberland Pharmaceuticals To Announce Third Quarter 2018 Financial Results
NASHVILLE, Tenn., Nov. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. A conference call and live Internet webcast will be held on Tuesday, November 13, 2018, at 4:30 p.m. Eastern Time to discuss the results.
Nov 06, 2018 07:30 am ET
Cumberland Pharmaceuticals To Acquire VIBATIV®
NASHVILLE, Tenn., Nov. 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a definitive agreement to acquire VIBATIV® from Theravance Biopharma. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Theravance Biopharma, Inc. is a diversified pharmaceutical organization with the core purpose of helping improve the lives of patients suffering from serious illness.
Nov 06, 2018 07:30 am ET
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
DUBLIN, Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Under the terms of the agreement, Cumberland will pay Theravance Biopharma a total of $25 million and tiered royalties of up to 20% on future US net product sales.
Sep 27, 2018 09:00 am ET
Newly Published Data Demonstrates Amifostine Delayed The Onset Of Acute Esophagitis For Small Cell Lung Cancer Patients
NASHVILLE, Tenn., Sept. 27, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, announce a new publication in Lung Cancer: Targets and Therapy of a contemporary retrospective series showing that subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage 3 small cell lung cancer patients treated with concomitant doublet chemotherapy and hyperfractionated radiotherapy.
Sep 24, 2018 10:00 am ET
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
NASHVILLE, Tenn., Sept. 24, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announced that Joe Galante, music industry executive, has joined its Board of Directors. He is the former Chairman of Sony Music in Nashville and President of RCA Records in New York City. Mr. Galante is also currently a member of the Board of Directors of Pinnacle Financial Partners, whose shares are listed on the NASDAQ stock exchange, as well as the Country Music Association and the chair of CMA Foundation.
Aug 14, 2018 04:05 pm ET
Cumberland Pharmaceuticals Reports Second Quarter 2018 Financial Results
NASHVILLE, Tenn., Aug. 14, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced second quarter 2018 financial results and Company update. Cumberland has a portfolio of seven U.S. Food and Drug Administration (FDA) approved brands. Net revenues for the quarter were $10.2 million, an increase of 17% over the prior year period and an 18% increase over the first quarter of this year. At the end of the second quarter, Cumberland had $90 million in tota
Aug 13, 2018 10:00 am ET
Cumberland Pharmaceuticals Appoints New Senior Executive
NASHVILLE, Tenn., Aug. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX) today announced the appointment of biopharmaceutical industry veteran Adam Haeberle, Ph.D. as senior director, clinical and regulatory affairs. His responsibilities will include overseeing Cumberland's product development team in support of its efforts to design and implement clinical studies.
Aug 07, 2018 04:05 pm ET
Cumberland Pharmaceuticals To Announce Second Quarter 2018 Financial Results
NASHVILLE, Tenn., Aug. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2018 financial results after the market closes on Tuesday, August 14, 2018. A conference call and live Internet webcast will be held on Tuesday, August 14, 2018, at 4:30 p.m. Eastern Time to discuss the results.
May 08, 2018 04:05 pm ET
Cumberland Pharmaceuticals Reports First Quarter 2018 Financial Results
NASHVILLE, Tenn., May 8, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced first quarter 2018 financial results. Net revenues for the period were $8.6 million, resulting in a net loss of $(2.4) million or $(0.15) per diluted share. As of March 31, 2018, Cumberland had $91 million in total assets, including approximately $51 million in cash and marketable securities.
May 01, 2018 09:35 am ET
Cumberland Pharmaceuticals To Announce First Quarter 2018 Financial Results
NASHVILLE, Tenn., May 1, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2018 financial results after the market closes on Tuesday, May 8, 2018. A conference call and live Internet webcast will be held on Tuesday, May 8, 2018, at 4:30 p.m. Eastern Time to discuss the results.
Apr 09, 2018 09:00 am ET
Cumberland Pharmaceuticals Expands into Oncology Support
NASHVILLE, Tenn., April 9, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals – announced today that it has expanded its medical specialties to include oncology-related medications. The company's entry into the oncology specialty includes two initial supportive care medications: Ethyol® (amifostine) injection and Totect® (dexrazoxane hydrochloride) injection.
Mar 26, 2018 09:35 am ET
Newly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria
NASHVILLE, Tenn., March 26, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announced today the publication of an open access article in Infection and Drug Resistance, with results demonstrating an 85% eradication rate of Helicobacter pylori (H. pylori) infection using clarithromycin-based triple therapy. Cumberland markets a branded clarithromycin-based triple therapy in the U.S. under the name Omeclamox®-Pak.
Mar 06, 2018 03:05 pm ET
Cumberland Pharmaceuticals Reports 25% Revenue Growth For The Full Year 2017
NASHVILLE, Tenn., March 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced fourth quarter and full year 2017 financial results. Net Revenues for the year ended December 31, 2017 were $41.2 million, a 25% increase over the prior year period.
Feb 27, 2018 03:05 pm ET
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2017 Financial Results
NASHVILLE, Tenn., Feb. 27, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2017 financial results after the market closes on Tuesday, March 6, 2018. A conference call and live Internet webcast will be held on Tuesday, March 6, 2018, at 4:30 p.m. Eastern Time to discuss the results.
Jan 30, 2018 08:35 am ET
Newly Published Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients
NASHVILLE, Tenn., Jan. 30, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, announce a new publication in Leukemia & Lymphoma, with study results showing that amifostine decreases gastro-intestinal (GI) toxicity in patients who receive treatment for their multiple myeloma. Cumberland markets branded amifostine in the U.S. under the name Ethyol®.
Nov 07, 2017 04:05 pm ET
Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter
NASHVILLE, Tenn., Nov. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2017 financial results with Net Revenues of $11.2 million, up 27% over the prior year quarter. It was the fifth consecutive quarter of year over year revenue growth for the Company, and during the first nine months of 2017 Net Revenues increased 23% over the prior year period.
Oct 31, 2017 05:05 pm ET
Cumberland Pharmaceuticals to Announce Third Quarter 2017 Financial Results
NASHVILLE, Tenn., Oct. 31, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2017 financial results after the market closes on Tuesday, November 7, 2017. A conference call and live Internet webcast will be held on Tuesday, November 7, 2017, at 4:30 p.m. Eastern Time to discuss the results.
Sep 25, 2017 09:00 am ET
Cumberland Pharmaceuticals Launches Promotion of Totect® in The U.S. for Emergency Oncology Intervention
NASHVILLE, Tenn. and BURTON ON TRENT, England, Sept. 25, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX, 'Cumberland') and Clinigen Group plc (AIM:CLIN, 'Clinigen'), announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S.
Aug 08, 2017 05:05 pm ET
Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter
NASHVILLE, Tenn., Aug. 8, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2017 financial results with Net Revenues of $8.7 million, up 17% over the prior year quarter. It was the fourth consecutive quarter of year over year revenue growth for the Company, and during the first half of 2017 Net Revenues increased 21% over the prior year period.
Aug 01, 2017 05:15 pm ET
Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results
NASHVILLE, Tenn., Aug. 1, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2017 financial results after the market closes on Tuesday, August 8, 2017. A conference call and live Internet webcast will be held on Tuesday, August 8, 2017, at 4:30 p.m. Eastern Time to discuss the results.
Jul 31, 2017 09:15 am ET
Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support
NASHVILLE, Tenn., July 31, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing dexrazoxane, sold under the brand name Totect®, to U.S. wholesalers today. Totect is an FDA-approved emergency oncology intervention indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the bod
May 15, 2017 05:05 pm ET
Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017
NASHVILLE, Tenn., May 15, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2017 financial results with Net Revenues of $9.6 million and Adjusted Earnings of $0.3 million or $0.02 per share. As of March 31, 2017, the Company had approximately $92 million in Total Assets including $50 million in cash and marketable securities.
May 08, 2017 05:05 pm ET
Cumberland Pharmaceuticals to Announce First Quarter 2017 Financial Results
NASHVILLE, Tenn., May 8, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2017 financial results after the market closes on Monday, May 15, 2017. A conference call and live Internet webcast will be held on Monday, May 15, 2017, at 4:30 p.m. Eastern Time to discuss the results.
Apr 26, 2017 09:00 am ET
New Kristalose® Growth Driver Established Through Co-Promotion Agreement
NASHVILLE, Tenn., April 26, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Poly Pharmaceuticals Inc., a privately-held U.S. specialty pharmaceutical company, have entered into a co-promotion partnership for Kristalose® within the United States. Poly's sales force will more than double the number of nationwide physicians called upon in support of the product.
Mar 27, 2017 05:15 pm ET
Caldolor® Demonstrates Significant Post Surgical Pain Reduction and Decrease in Opioid Use
NASHVILLE, Tenn., March 27, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a trial providing evidence that using Caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in patients undergoing transsphenoidal surgery. The trial was conducted at the Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center in Phoenix, Arizona, and was published in the Journal of Neurosurgery, March 2017.
Mar 07, 2017 04:15 pm ET
Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results
NASHVILLE, Tenn., March 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and full year 2016 financial results. Net Revenues for the year ended December 31, 2016 were $33.0 million with Adjusted Earnings of $1.8 million or $0.11 per share.
Feb 28, 2017 04:15 pm ET
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2016 Financial Results
NASHVILLE, Tenn., Feb. 28, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2016 financial results after the market closes on Tuesday, March 7, 2017. A conference call and live Internet webcast will be held on Tuesday, March 7, 2017, at 4:30 p.m. Eastern Time to discuss the results.
Feb 07, 2017 08:15 am ET
Caldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics
NASHVILLE, Tenn., Feb. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a multicenter clinical study demonstrating that Caldolor® (ibuprofen) Injection delivered significant fever reduction in hospitalized children. This study, which adds to the growing body of literature supporting Caldolor, evaluated the efficacy and safety of intravenous ibuprofen in pediatric patients, six months and older, with fever. This pivotal data supported the FDA approval of Caldolor for use in this pediatric patient population.
Jan 30, 2017 08:15 am ET
U.S. Court Of Appeals Affirms Cumberland Pharmaceuticals' Victory In Patent Litigation Case
NASHVILLE, Tenn., Jan. 30, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced that on January 26, 2017, the U.S. Court of Appeals for the Federal Circuit ruled in favor of Cumberland in a patent case associated with its Acetadote® product.
Jan 16, 2017 08:15 am ET
Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors
NASHVILLE, Tenn., Jan. 16, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce the addition of Kenneth J. Krogulski, CFA to its Board of Directors. He is the President and Chief Executive Officer of Berkshire Asset Management LLC. He is also the Chief Investment Officer of Berkshire, a 30-year-old independent SEC registered investment advisory firm with over $1.5 billion under management.
Jan 09, 2017 09:30 am ET
Cumberland Pharmaceuticals and Clinigen Enter Exclusive U.S. Commercialization Agreement For Totect®
NASHVILLE, Tenn., Jan. 9, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, announce an exclusive agreement to commercialize the oncology support drug, Totect® (dexrazoxane hydrochloride) in the U.S.
Nov 16, 2016 08:00 am ET
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
NASHVILLE, Tenn., Nov. 16, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. The product line is approved for patient use in various European countries. Cumberland will register and commercialize the methotrexate products in the United St
Nov 07, 2016 08:30 am ET
Cumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Nov 07, 2016 08:30 am ET
Cumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Nov 01, 2016 05:05 pm ET
Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results
NASHVILLE, Tenn., Nov. 1, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2016 financial results with Net Revenues of $8.8 million and Adjusted Earnings of $1.0 million or $0.06 per share. Earnings prior to adjustments were $0.1 million or $0.01 per share.
Oct 31, 2016 12:10 pm ET
Public Company Executives to Present Online to Investors on November 3
NEW YORK, Oct. 31, 2016 /CNW/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the upcoming VirtualInvestorConferences.com, the evergreen online investor conference series. Individual investors, institutional investors, advisors, and analysts are invited. The show opens on at 9:00 AM ET, with the first live webcast at 9:15 AM ET, on Thursday, November 3.
Oct 31, 2016 12:10 pm ET
Public Company Executives to Present Online to Investors on November 3
NEW YORK, Oct. 31, 2016 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the upcoming VirtualInvestorConferences.com, the evergreen online investor conference series. Individual investors, institutional investors, advisors, and analysts are invited. The show opens on at 9:00 AM ET, with the first live webcast at 9:15 AM ET, on Thursday, November 3.
Oct 28, 2016 09:30 am ET
Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com November 3
NASHVILLE, Tenn., Oct. 28, 2016 /CNW/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), based in Nashville, focused on specialty pharmaceuticals, today announced that A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals, will present live at VirtualInvestorConferences.com on November 3, 2016.
Oct 28, 2016 09:30 am ET
Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com November 3
NASHVILLE, Tenn., Oct. 28, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), based in Nashville, focused on specialty pharmaceuticals, today announced that A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals, will present live at VirtualInvestorConferences.com on November 3, 2016.
Oct 25, 2016 05:05 pm ET
Cumberland Pharmaceuticals To Announce Third Quarter 2016 Financial Results
NASHVILLE, Tenn., Oct. 25, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2016 financial results after the market closes on Tuesday, November 1, 2016. A conference call and live Internet webcast will be held on Tuesday, November 1, 2016, at 4:30 p.m. Eastern Time to discuss the results.
Sep 26, 2016 09:30 am ET
Cumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient Support
NASHVILLE, Tenn., Sept. 26, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), announced today that it has launched the U.S. promotion of Ethyol® (amifostine) for Injection, a hospital-based product used to treat oncology patients. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. Cumberland entered into
Sep 14, 2016 05:05 pm ET
Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension
NASHVILLE, Tenn., Sept. 14, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), today announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study.
Aug 23, 2016 05:05 pm ET
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support
NASHVILLE, Tenn., Aug. 23, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients
Aug 02, 2016 05:05 pm ET
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results
NASHVILLE, Tenn., Aug. 2, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2016 financial results with Net Revenues of $7.4 million and Adjusted Earnings of $0.7 million or $0.04 per share.
Jul 26, 2016 05:05 pm ET
Cumberland Pharmaceuticals To Announce Second Quarter 2016 Financial Results
NASHVILLE, Tenn., July 26, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release second quarter 2016 financial results after the market closes on Tuesday, August 2, 2016. A conference call and live Internet webcast will be held on Tuesday, August 2, 2016, at 4:30 p.m. Eastern Time to discuss the results.
Jul 18, 2016 10:00 am ET
Cumberland Pharmaceuticals To Participate In Avondale Partners' 4th Annual Healthcare Conference
NASHVILLE, Tenn., July 18, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations today announced that management will participate in the 4th Annual Avondale Partners Healthcare 1-1 Conference in Boston. The conference is being held August 10, 2016 at the Boston Harbor Hotel in Boston. Mass.
Jun 10, 2016 09:00 am ET
Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors
NASHVILLE, Tenn., June 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is pleased to announce the addition of Caroline Young to its Board of Directors. Caroline is the prior President of the Nashville Health Care Council and founding Executive Director of the Tennessee Biotechnology Association.
May 10, 2016 05:05 pm ET
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results
NASHVILLE, Tenn., May 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2016 financial results with Net Revenues of $7.7 million and Adjusted Earnings of $0.3 million or $0.02 per share.
May 10, 2016 08:00 am ET
Cumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement for oncology support drug Ethyol®
NASHVILLE, Tenn., May 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. ('Cumberland', NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc ('Clinigen', AIM: CLIN), the global pharmaceutical and services company, have signed an exclusive agreement to commercialize the oncology support drug, Ethyol® (amifostine), in the U.S. This is the first product Clinigen has licensed to Cumberland under the strategic alliance entered into late last year.
May 03, 2016 05:15 pm ET
Cumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results
NASHVILLE, Tenn., May 3, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016. A conference call and live Internet webcast will be held on Tuesday, May 10, 2016, at 4:30 p.m. Eastern Time to discuss the results.
Apr 27, 2016 09:00 am ET
Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis
NASHVILLE, Tenn., April 27, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, announced today the addition of VASCULANTM to its pipeline. Cumberland has initiated the clinical development of VasculanTM (ifetroban) oral capsule for the treatment of systemic sclerosis. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for Phase II clinical program for Vasculan in patients with systemic sclero
Mar 24, 2016 08:30 am ET
Caldolor® Launched For The Treatment Of Pain And Fever In Children
NASHVILLE, Tenn., March 24, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) a specialty pharmaceutical company, today announced the launch of Caldolor® (ibuprofen) injection for pediatric patients. This launch follows the U.S. Food and Drug Administration (FDA) approval of Caldolor for the treatment of pain and fever in children six months of age and older. Caldolor is an injectable form of ibuprofen designed primarily for hospitalized patients who are not able to tolerate their pain and fever medications orally. It is the first and only injectable non-steroidal anti-infla
Mar 03, 2016 04:05 pm ET
Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
NASHVILLE, Tenn., March 3, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter 2015 financial results with Net Revenues of $8.0 million and Adjusted Earnings of $0.6 million or $0.03 per share. Net Revenues for the year ended December 31, 2015 were $33.5 million with Adjusted Earnings of $4.5 million or $0.26 per share.
Feb 25, 2016 04:05 pm ET
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2015 Financial Results
NASHVILLE, Tenn., Feb. 25, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2015 financial results after the market closes on Thursday, March 3, 2016. A conference call and live Internet webcast will be held on Thursday, March 3, 2016, at 4:30 p.m. Eastern Time to discuss the results.
Feb 10, 2016 08:30 am ET
Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics
NASHVILLE, Tenn., Feb. 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of an open label multicenter study adding to the growing body of literature that supports Vaprisol® (conivaptan) Injection. The study evaluated both 20 and 40 mg/day doses of conivaptan in hyponatremic patients. The new publication is currently available as open access articles in the journal Drug Design, Development and Therapy.
Jan 25, 2016 08:00 am ET
Piramal Critical Care And Cumberland Pharmaceuticals Announce Launch Of Caldolor And Vaprisol Co-Promotion
BETHLEHEM, Pa. and NASHVILLE, Tenn., Jan. 25, 2016 /PRNewswire/ -- Piramal Critical Care, an integral business unit of Piramal Enterprises Limited (NSE: PEL, BSE: 500302), and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, announced today that they have officially launched co-promotion of two of Cumberland's branded hospital products, Caldolor® and Vaprisol® throughout the United States.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.